<DOC>
	<DOCNO>NCT00139815</DOCNO>
	<brief_summary>Study Objectives PRIMARY OBJECTIVE : To evaluate whether fondaparinux least effective superior enoxaparin prevent death , myocardial infarction refactory ischemia Day 9 acute treatment patient unstable angina/non ST-segment elevation myocardial infarction concurrently manage standard medical therapy . SECONDARY OBJECTIVE : If non inferiority fondaparinux establish initial statistical analysis second step , superiority fondaparinux enoxaparin evaluate statistically . - To determine whether fondaparinux superior enoxaparin reduce death MI Day 9 - To determine whether fondaparinux superior enoxaparin reduce major bleed event Day 9 - To determine whether relative effect primary end point fondaparinux versus enoxaparin sustain Day 14 , Day 30 , Day 90 Day 180 Study Drug : Patients randomize receive either : - Fondaparinux 2.5 mg placebo-enoxaparin twice daily subcutaneous injection - Enoxaparin ( 1mg/kg ) twice fondaparinux-placebo daily subcutaneous injection Duration Therapy : - Fondaparinux 2.5mg daily 8 day hospital discharge ( whichever earlier ) - Enoxaparin 1mg/kg b.i.d . x 2-8 day clinically stable . - Patients receive ASA standard medical therapy . Substudy : - A substudy compare routine early coronary angiography immediately soon possible ( later 24 hour randomization ) intervention versus delay ( &gt; 48 hr ) coronary angiography intervention . Primary Outcome : The first occurence component follow composite Day 9 : - Death - Myocardial Infarction - Refractory Ischemia</brief_summary>
	<brief_title>Michelangelo - Oasis 5</brief_title>
	<detailed_description>This double-blind , double-dummy , randomize , parallel-group , controlled trial compare safety efficacy fondaparinux enoxaparin subject UA/NSTEMI ( unstable angina/non ST segment myocardial infarction ) . Study drug ( s.c. ) start immediately follow randomization ; subject receive fondaparinux 2.5mg daily s.c 8 day hospital discharge , early , enoxaparin 1mg/kg twice daily s.c 2 8 day clinically stable . In subject creatinine clearance 20mL/min 30mL/min , enoxaparin administer 1mg/kg daily . In addition study drug , subject receive standard medical care , include intervention ( PCI [ percutaneous coronary intervention ] coronary artery bypass graft surgery [ CABG ] ) .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients present admitted hospital symptom suspect represent acute coronary syndrome . Able randomize within 24 hour onset recent episode symptom . At least one follow additional criterion : ( 1 ) Troponin T I CKMB upper limit normal local institution and/or ( 2 ) ECG change compatible ischemia Written inform consent Age &lt; 21 year Any contraindication low molecular weight heparin Hemorrhagic stroke within last 12 month Indication anticoagulation ACS . Pregnancy woman childbearing potential use effective method contraception Comorbid condition life expectancy le 6 month Prior enrollment one fondaparinux ACS trail currently receive experimental pharmacologic agent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>unstable angina</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>fondaparinux sodium</keyword>
	<keyword>non ST segment elevation myocardial infarction</keyword>
	<keyword>myocardial infarction</keyword>
</DOC>